Surovatamig

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameSurovatamig
Drug Alias NameCD19 x CD3 T-BsAbTNB-486AZD-0486AZD0486
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD19CD3 T-cell engagersAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsLarge B Cell LymphomaAutoimmune DiseasesLupus Erythematosus, Systemic +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[26] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTeneobio Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstraZeneca global R & D (China) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsLarge B Cell LymphomaAutoimmune DiseasesLupus Erythematosus, Systemic +[12] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A